OBJECTIVES: The aim of this study was to describe our experience in the control of active CMV infection following HSCT using two strategies of CMV infection treatment: ganciclovir universal prophylaxis at low doses and pre-emptive therapy with ganciclovir. METHODS: The surveillance was based on the monitoring of antigenaemia (AGM) and on a nested polymerase chain reaction (N-PCR) for the detection of CMV in both strategies. Forty-five recipients with malignant diseases and with a risk for CMV disease received universal prophylaxis (Group A). The non-treated group consisted of 24 patients, most of them with non-malignant diseases who did not receive universal prophylaxis (Group B). RESULTS: In Group A, the incidence of positive AGM was 51%, with a positive PCR of 68.9%. In Group B, the AGM positivity was 66.7% and that of N-PCR was 66.7%. CMV disease occurred in 6/55 patients (10.9%), with 2/36 (5.5%) from Group A and 4/19 (21%) from Group B. Two of these six patients (33.3%) died of CMV disease. CONCLUSIONS: Our result suggests that AGM and N-PCR can be used as markers for assessing the monitoring and the introduction pre-emptive therapy. This approach could prove to be more cost-effective than ganciclovir universal prophylaxis for treating CMV infection.
OBJECTIVES: The aim of this study was to describe our experience in the control of active CMV infection following HSCT using two strategies of CMV infection treatment: ganciclovir universal prophylaxis at low doses and pre-emptive therapy with ganciclovir. METHODS: The surveillance was based on the monitoring of antigenaemia (AGM) and on a nested polymerase chain reaction (N-PCR) for the detection of CMV in both strategies. Forty-five recipients with malignant diseases and with a risk for CMV disease received universal prophylaxis (Group A). The non-treated group consisted of 24 patients, most of them with non-malignant diseases who did not receive universal prophylaxis (Group B). RESULTS: In Group A, the incidence of positive AGM was 51%, with a positive PCR of 68.9%. In Group B, the AGM positivity was 66.7% and that of N-PCR was 66.7%. CMV disease occurred in 6/55 patients (10.9%), with 2/36 (5.5%) from Group A and 4/19 (21%) from Group B. Two of these six patients (33.3%) died of CMV disease. CONCLUSIONS: Our result suggests that AGM and N-PCR can be used as markers for assessing the monitoring and the introduction pre-emptive therapy. This approach could prove to be more cost-effective than ganciclovir universal prophylaxis for treating CMV infection.
Authors: Renata M B Peres; Cláudia R C Costa; Paula D Andrade; Sandra H A Bonon; Dulcinéia M Albuquerque; Cristiane de Oliveira; Afonso C Vigorito; Francisco J P Aranha; Cármino A de Souza; Sandra C B Costa Journal: BMC Infect Dis Date: 2010-06-01 Impact factor: 3.090
Authors: Fernanda Aparecida Costa; Marcelo Naoki Soki; Paula Durante Andrade; Sandra Helena Alves Bonon; Ronaldo Luis Thomasini; Ana Maria Sampaio; Marcelo de Carvalho Ramos; Claudio Lúcio Rossi; Teresa Cristina Cavalcanti; Ilka de Fatima Boin; Marília Leonard; Luiz Sérgio Leonard; Raquel Bello Stucchi; Sandra Cecília Botelho Costa Journal: Clinics (Sao Paulo) Date: 2011 Impact factor: 2.365
Authors: Samah Aly Loutfy; Maha A Abo-Shadi; Mohamed Fawzy; Mohamed El-Wakil; Shimaa A Metwally; Manar M Moneer; Nasra F Abdel Fattah; Sara Kassem; Ahmed Elgebaly Journal: Virol J Date: 2017-03-06 Impact factor: 4.099
Authors: Débora C Dieamant; Sandra H A Bonon; Renata M B Peres; Claudia R C Costa; Dúlcinéia M Albuquerque; Eliana C M Miranda; Francisco J P Aranha; Gislaine Oliveira-Duarte; Virginio C A Fernandes; Carmino A De Souza; Sandra C B Costa; Afonso C Vigorito Journal: BMC Infect Dis Date: 2013-07-10 Impact factor: 3.090
Authors: Laura Diaz; Joaquin Rosales; Fernando Rosso; Maria Rosales; Mayra Estacio; Eliana Manzi; Francisco Javier Jaramillo Journal: Hematol Transfus Cell Ther Date: 2019-02-22